C
Constance M. Yuan
Researcher at National Institutes of Health
Publications - 133
Citations - 10629
Constance M. Yuan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Multiple myeloma. The author has an hindex of 35, co-authored 133 publications receiving 8169 citations.
Papers
More filters
Journal ArticleDOI
Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).
Nirali N. Shah,Maureen M. O'Brien,Constance M. Yuan,Lingyun Ji,Xinxin Xu,Susan R. Rheingold,Deepa Bhojwani,Joanna Yi,Andrew C. Harris,Patrick A. Brown,Michael J. Borowitz,Meenakshi Devidas,Elizabeth A. Raetz,Lia Gore,Mignon L. Loh +14 more
TL;DR: Results from the COG AALL1621 phase 2 trial evaluated the efficacy of InO in children and young adults with relapsed/refractory CD22+ B-cell ALL report results of central surface CD22 expre...
Journal ArticleDOI
Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome By Rational Redesign of CAR Signaling Domains
Robbie G. Majzner,Skyler P. Rietberg,Louai Labanieh,Elena Sotillo,Evan W. Weber,Rachel C. Lynn,Johanna Theruvath,Constance M. Yuan,Peng Xu,Sang M. Nguyen,Nirali N. Shah,Maryalice Stetler-Stevenson,Terry J. Fry,Daniel W. Lee,Crystal L. Mackall +14 more
TL;DR: The choice of costimulatory domain in CAR T cells plays a major role in modulating activity against low antigen density tumors, and a CAR with two copies of intracellular zeta in the signaling domain demonstrated enhanced cytotoxicity, proliferation, cytokine production, and pERK signaling.
Journal ArticleDOI
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Final Results from the NCI Phase 2 Pilot Study
Ola Landgren,Ola Landgren,Mark Roschewski,Sham Mailankody,Mary Kwok,Elisabet E. Manasanch,Manisha Bhutani,Nishant Tageja,Dickran Kazandjian,Adriana Zingone,Rene Costello,Debra Burton,Yong Zhang,Peter Wu,George Carter,Marcia Mulquin,Diamond Zuchlinski,Ashley Carpenter,Verena Gounden,Candice Morrison,Irina Maric,Katherine R. Calvo,Raul C. Braylan,Constance M. Yuan,Maryalice Stetler-Stevenson,Diane C. Arthur,Liza Lindenberg,Kurdziel Karen,Peter L. Choyke,Seth M. Steinberg,William D. Figg,Neha Korde,Neha Korde +32 more
TL;DR: Early treatment with carfilzomib, lenalidomide, and dexamethasone was associated with high rates of complete response and minimal residual disease negativity by multi-color flow cytometry, next-generation sequencing, and FDG-PET/CT in patients with high-risk smoldering multiple myeloma.
Journal ArticleDOI
Intensification of Lymphodepletion Optimizes CAR Re-Treatment Efficacy
Haneen Shalabi,Nirali N. Shah,Terry J. Fry,Bonnie Yates,Cynthia Delbrook,Constance M. Yuan,Maryalice Stetler-Stevenson,Sneha Ramakrishna +7 more
TL;DR: In this paper, the role of antigen expression on treatment response was explored for CAR re-treatment in children and young adults with relapsed/refractory CD22+ acute lymphoblastic leukemia (ALL).
Proceedings ArticleDOI
Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
Haneen Shalabi,Bonnie Yates,Shilpa A Shahani,Haiying Qin,Steven L. Highfill,Sandhya R. Panch,Minh Tran,David F. Stroncek,Leah Hoffman,Lauren Little,Katherine Graap,Maryalice Stetler-Stevenson,Constance M. Yuan,Hao-Wei Wang,Terry J. Fry,Nirali N. Shah +15 more
TL;DR: In the preliminary experience, CD19/22 CAR was well tolerated and effective in CAR naive patients, with 4/6 patients achieving MRD negative CR and Relapses were antigen positive likely due to limited CAR persistence.